Zhang Haoren founded True Health Medical Technology in 2018 with a bold conviction: that the future of cancer treatment lay not in grand surgical robots, but in the millimeter-precise guidance of needles inserted deep into the body. Now, the Guangdong-based company is taking its vision public, filing for a Hong Kong listing to capture what may be one of the world's smallest—and fastest-growing—niches in medical robotics.
While household names like MicroPort MedBot dominate the laparoscopic surgery market with broader appeal and established demand, True Health has charted a different course. The company specializes in robotic systems that guide percutaneous puncture and microwave ablation procedures—the delicate work of accessing tumors in the lung, liver, and kidney with pinpoint accuracy. It is a far more specialized field, but one where precision can mean the difference between successful diagnosis and catastrophic error.
The market True Health is entering remains embryonic. China's puncture and ablation robotics sector was worth only 40.3 million yuan—roughly $5.9 million—in 2024. But the potential is staggering: third-party data cited in the company's IPO application projects the market will expand to 2.33 billion yuan by 2032, representing a compound annual growth rate of 66 percent. For now, True Health dominates what exists. From 2022 to 2024, the company ranked first in China by revenue in this category and holds the sector's highest number of approved precision devices.
The centerpiece of its portfolio is the TH-X MW, described as the world's first image-guided microwave ablation robot—and the first innovative medical device approved in the highest regulatory category in the Hengqin zone of Guangdong province, a sign of both technological ambition and government backing. The company also offers what it describes as China's first domestically developed system for percutaneous puncture navigation. By mid-2024, True Health's devices had been deployed across more than 20 provinces and nearly 100 medical institutions, supporting more than 5,000 clinical procedures. That clinical footprint, while small in absolute terms, could become a crucial competitive moat as the market matures and hospitals make procurement decisions.
Yet the company faces real headwinds. True Health remains intensely dependent on a tiny customer base: its top five clients accounted for 100 percent of revenue in 2023, 2024, and the first half of 2025, with a single customer contributing nearly 90 percent. Its revenue base is minimal, its business model unproven, and the path to sustainable profitability remains unclear. China's strict volume-based procurement system and rigid cost controls add additional complexity.
What True Health represents, though, is a different kind of medical robotics opportunity—one that sits at the intersection of an underserved clinical need and explosive projected growth. Medical robots took decades to prove their value in surgery; puncture and ablation guidance is still in its infancy. The company's recent relocation of its headquarters from Beijing to Hengqin signals deep alignment with provincial healthcare ambitions. For investors convinced that precision medicine and robotics will reshape cancer diagnosis and treatment, True Health offers a rare chance to enter the ground floor of a niche that few are watching—yet.